Recently, an insider trading scandal rocked Jacob Gottlieb’s old investment firm Visium. While he is adamant about not having anything to do with the actions of the small group of employees that were called out by a whistleblower, he still agreed to pay $10 million in fines and other expenses and begin the process of closing the company. Instead of letting the mistakes of a few ruin his career, he looked at the events like a fresh start and began creating Altium.
Altium will be acting in a rather similar fashion as Jake Gottlieb’s old company as it will mainly handle investments in different healthcare fields like medical devices and pharmaceuticals. In addition to the decades of experience that Jake Gottlieb has in investing, he will also have the knowledge of Stuart Weisbrod. The 2 got to know each other when Jacob Gottlieb worked as a portfolio manager for Weisbrod’s healthcare investment firm Merlin BioMed Group. While Jake Gottlieb was working for the company, he was able to show considerable returns on his portfolio while the industry was seeing a revolution in biotechnology.
Eventually, the decision was made to close Merlin’s doors and the investors decided to go their separate ways to create their own companies. It may have been around 2 decades since Jake Gottlieb and Weisbrod have worked in the same office, but the pair is already excited about the potential prospects they have in investing. One of the first big deals that Altium has made involves the development of a capsule that allows patients to take protein-based therapies by mouth. This capsule in development by Oramed may have the most potential for patients with diabetes who have no other options besides injecting their insulin.
Oramed isn’t the first company to try to develop this type of technology, but they are the first to have possibly found a solution that allows the medication to stay viable long enough to be processed by the body. Jacob Gottlieb believes that it will not only help increase comfort but also reduce risks. Infections are always a concern when it comes to diabetic injection sites.
Find out more about Jake Gottlieb Altium: https://ideamensch.com/jacob-gottlieb/